Mineral trioxide aggregate vs. formocresol in pulpotomized primary molars: a preliminary report.
OBJECTIVE
The aim of this study was to compare the effect of mineral trioxide aggregate (MTA) to that of formocresol (FC) as pulp dressing agents in pulpotomized primary molars with carious pulp exposure.


METHODS
Forty-five primary molars of 26 children were treated by a conventional pulpotomy technique. The teeth were randomly assigned to the MTA (experimental) or FC (control) group by a toss of a coin. Following removal of the coronal pulp and hemostasis the pulp stumps were covered with an MTA paste in the experimental group. In the control group, FC was placed with a cotton pellet over the pulp stumps for 5 minutes and removed; the pulp stumps were then covered by zinc oxide-eugenol (ZOE) paste. The teeth of both groups were restored with stainless steel crowns. Eighteen children with 32 teeth arrived for clinical and radiographic follow-up evaluation ranging from 6 to 30 months.


RESULTS
The follow-up evaluations revealed only one failure (internal resorption detected at a 17 months postoperative evaluation) in a molar treated with formocresol. None of the MTA-treated teeth showed any clinical or radiographic pathology. Pulp canal obliteration was observed in 9 of 32 (28%) evaluated molars. This finding was detected in 2 out of the 15 teeth treated with FC (13%) and in 7 out of the 17 treated with MTA (41%).


CONCLUSIONS
MTA showed clinical and radiographic success as a dressing material following pulpotomy in primary teeth and seems to be a suitable replacement for formocresol in primary teeth.
Eidelman
E
E
Department of Pediatric Dentistry, Hebrew University, Hadassah School of Dental Medicine, Jerusalem, Israel. eeliezer@cc.huji.ac.il
Holan
G
G
Fuks
A B
AB
D017607:Aluminum Compounds / Q000627:therapeutic use*; D017610:Calcium Compounds / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D002648:Child; D002675:Child, Preschool; D003442:Crowns; D003731:Dental Caries / Q000150:complications; D003785:Dental Pulp Capping; D003786:Dental Pulp Cavity / Q000000981:diagnostic imaging; D003789:Dental Pulp Exposure / Q000628:therapy; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D005566:Formocresols / Q000627:therapeutic use*; D006488:Hemostasis, Surgical; D006801:Humans; D008297:Male; D008963:Molar / Q000000981:diagnostic imaging / Q000601:surgery; D010087:Oxides / Q000627:therapeutic use*; D011672:Pulpotomy / Q000379:methods*; D011859:Radiography; D012391:Root Resorption / Q000209:etiology; D017640:Silicates / Q000627:therapeutic use*; D013193:Stainless Steel; D014094:Tooth, Deciduous / Q000000981:diagnostic imaging / Q000601:surgery; D016896:Treatment Outcome; D015035:Zinc Oxide-Eugenol Cement / Q000627:therapeutic use
D017607:Aluminum Compounds; D017610:Calcium Compounds; D004338:Drug Combinations; D005566:Formocresols; D010087:Oxides; D017640:Silicates; D015035:Zinc Oxide-Eugenol Cement; C086631:mineral trioxide aggregate; D013193:Stainless Steel; C031025:formocresol